Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Acquires UK Software Firm Momentum Healthcare

NEW YORK, July 12 - Cellomics, the Pittsburgh, PA-based maker of integrated informatics and cell-screening technologies, has acquired Momentum Healthcare, a developer of drug discovery software, the company said Thursday.

Terms of the deal, which was formalized today but has been under negotiation for some time, were not disclosed and a company official declined to comment immediately.

Ian Shaw, the CEO of Momentum, has relocated from the company's headquarters in Southampton and Cardiff, UK, to Pittsburgh to take the position as vice president of therapeutic discovery for Cellomics. Mark Collins of Momentum has also moved to the US to become Cellomics' senior director of pharmaceutical informatics.   

This merger comes eight months after Cellomics postponed its initial public offering.

 

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.